{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-014570","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2023-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.855129+00:00","generated_at":"2026-06-15T00:55:21.426000+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Zevra Therapeutics CEO resigns; Q1 net loss widens to $11.8M, revenue $2.9M","bullets":["CEO Richard W. Pascoe resigns effective June 1, 2023; Chief Development Officer Christal Mickle appointed interim CEO.","Q1 net loss of $11.8M ($0.34 per share) vs $1.9M loss a year ago; revenue fell to $2.9M from $4.0M.","Cash and investments $95.3M; expects operating runway into 2026, funding arimoclomol NDA resubmission and KP1077 program.","Arimoclomol NDA resubmission for NPC anticipated as early as Q3 2023; KP1077 Phase 2 IH interim data expected Q3 2023.","Share repurchases of 665,739 shares for ~$3.4M during Q1; $39.1M remaining under program."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-014570","json":"https://secwatch.observer/filing/0001437749-23-014570.json","markdown":"https://secwatch.observer/filing/0001437749-23-014570.md","text":"https://secwatch.observer/filing/0001437749-23-014570.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923014570/0001437749-23-014570-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923014570/kmph20230112_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T00:55:21.426000+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"89efe1146e0d0ad6fd5cf15b9d3064527577766b","claim":"ZEVRA THERAPEUTICS, INC. reported first quarter ended March 31, 2023 results: EPS ($0.34) per basic and diluted share.","evidence_excerpt":"Net revenue for Q1 2023 was $2.9 million compared to Q1 2022 net revenue of $4.0 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923014570/0001437749-23-014570-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"EPS","value":"($0.34) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"89efe1146e0d0ad6fd5cf15b9d3064527577766b","claim":"ZEVRA THERAPEUTICS, INC. reported first quarter ended March 31, 2023 results: EPS ($0.34) per basic and diluted share.","evidence_excerpt":"Net loss attributable to common stockholders for Q1 2023 was ($11.8) million, or ($0.34) per basic and diluted share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923014570/0001437749-23-014570-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"EPS","value":"($0.34) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a8fe292af8","claim":"Richard W. Pascoe resigned as Chief Executive Officer at ZEVRA THERAPEUTICS, INC..","evidence_excerpt":"As previously reported, Richard W. Pascoe resigned as Zevra’s Chief Executive Officer, effective as of the Effective Date.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923014570/0001437749-23-014570-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"d05fa1aafa","claim":"Christal M. M. Mickle was appointed as interim President and Chief Executive Officer at ZEVRA THERAPEUTICS, INC..","evidence_excerpt":"On May 13, 2023, Zevra’s Board of Directors (the “Board”) appointed Christal M.M. Mickle, Zevra’s Chief Development Officer, as Zevra’s interim President and Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774923014570/0001437749-23-014570-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"interim President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}